Current aspects
The right dosage may vary depending on the patients needs
Nandoe Tewarie RDS, Hurtado A, Ritfeld GJ, Rahiem ST, Wendell DF, Barroso MMS, et al
For Canadians dealing with metabolic syndrome, prediabetes, or elevated cardiovascular risk markers, the possibility of targeted visceral fat reduction adds a health dimension beyond cosmetic weight loss
Orally administered liposomal technology has emerged as a promising remedy to low nutritional bioavailability.2 Liposomes made of synthetic materials are currently used by pharmaceutical companies for improved drug delivery.3 However, cutting edge supplement companies are using a natural methodology to deliver a variety of low-bioavailability materials that include vitamins (e.g
Interestingly, Saxendas United States patent is set to expire, and generic versions of this medication MAY be available as early as June of 2024